Shahnawaz Amdani, MD

Appointed
2018

Education & Fellowships

Fellowship - St. Louis Children`s Hospital
Pediatric Heart Failure and Transplantation
St. Louis, MO
2018

Fellowship - Children's Hospital of Michigan
Pediatric Cardiology
Detroit, MI United States
2017

Residency - Lincoln Medical and Mental Health Center
Pediatrics
Bronx, NY
2014

Medical Education - SMT N H L Municipal Medical College
Ahmedabad,
2009

Professional Highlights

• BIBLIOGRAPHY

  Peer Reviewed Articles

  1. Bansal N, Amdani SM, Hutchins KK, Lipshultz SE, "Cardiovascular disease in survivors of childhood cancer", Curr Opin Pediatr., 2018, 30(5), 628-638

  2. Amdani SM, Mian MUM, Thomas RL, Ross RD, "NT-pro BNP-A marker for worsening respiratory status and mortality in infants and young children with pulmonary hypertension", Congenit Heart Dis, 2018, 13(4), 499-505

  3. Amdani SM, Du W, Aggarwal S, "Outcome of pediatric heart transplantation in blood culture positive donors in the United States", Clin Transplant, 2018, 32(5), e13249

  4. Amdani SM, Kim HS, Orvedahl A, John AO, Said A, Simpson K, "Successful treatment of fulminant neonatal enteroviral myocarditis in monochorionic diamniotic twins with cardiopulmonary support, intravenous immunoglobulin and pocapavir.", BMJ Case Rep., 2018

  5. Amdani SM, Ross RD, Webster Jr PA, Turner DR, Forbes TJ, Kobayashi D, "Reducing radiation exposure by lowering frame rate in children undergoing cardiac catheterization: A quality improvement study.", Congenit Heart Dis, 2018

  6. Amdani SM, Sallaam S, Karpawich PP, Aggarwal S, "Utility of Echocardiography in Detecting Silent Complications After Pediatric Catheter Ablations", Pediatr Cardiol, 2017, 38(7), 1426-1433

  7. Amdani SM, Sanil Y, "Infantile Pompe Disease and Enzyme Replacement Therapy", J Paediatr Child Health, 2017, 53(12), 1242- 1243

  8. Bansal N, Amdani S, Lipshultz ER, Lipshultz SE, "Chemotherapy-induced cardiotoxicity in children", Expert Opin Drug Metab Toxicol, 2017, 13(8), 817-832

  9. Amdani S, Karpawich PP, "Atrial Arrhythmias in Adults with Repaired Congenital Heart Disease. J Clin Trial Cardiol", J Clin Trial Cardiol, 2015, 2(3), 1-5

  Book Chapters

  1. Amdani SM, Bansal N, Lipshultz ER, Adams J, Lipshultz SE, "Survivorship (part 2): Pediatric Cancer Survivors." In: Susan Dent (editors), "Practical Cardio-oncology ", 1st edition, Taylor & Francis, Abingdon, 2019

  2. Amdani SM, Ross RD, "Evaluation and Management of Pediatric Chest Pain, Syncope, and Murmur in the Emergency Department" In: Sarnaik AP, Ross RD, Lipshultz SE, Walters III HL (editors), "Cardiac Emergencies in Children: A Practical Approach to Diagnosis and Management", 1st edition, Springer, New York, 2018

  3. Amdani SM, Bansal N, Franco VI, Adams MJ, Lipshultz SE, "Cardiovascular effects of anthracycline chemotherapy and radiation therapy in children with cancer." In: Joerg Herrmann (editors), "Clinical Cardio-oncology", Elsevier, Atlanta, 2016

  Editorials

  1. Bansal N, Barach P, Amdani SM, Lipshultz SE., "When is early septal myectomy in children with hypertrophic cardiomyopathy justified?", Transl Pediatr , 2018, 7(4), 362-366

  Letters

  1. Amdani SM, "Redesigning Ventricular Assist Devices to Protect Ethnic Minorities: Changing Design With Changing Times", JACC Heart Fail, 2016, 4(10), 831-832

  Specialty Interests

  Pediatric Heart Failure
  Pediatric Heart Transplantation
  Pediatric Cardiomyopathy (Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy, Restrictive Cardiomyopathy, Left ventricular non-compaction)
  Failing Fontan (Fontan patients with ventricular dysfunction, significant growth derangement, cachexia, protein losing enteropathy, plastic bronchitis, liver dysfunction)
  Cardiomyopathy in childhood cancer survivors
  Cardiomyopathy secondary to neuromuscular diseases

Certifications

• Pediatrics
• Pediatrics - Pediatric Cardiology

Specialty Interests

Pediatric Heart Failure Pediatric Heart Transplantation Dilated Cardiomyopathy Hypertrophic Cardiomyopathy Restrictive Cardiomyopathy Failing Fontans (Fontan patients with ventricular dysfunction, protein losing enteropathy, plastic bronchitis

Awards & Honors

• Elected Fellow of the American College of Cardiology, 01/2019
• American College of Cardiology Fellow in Training Legislative Conference Travel Award, 07/2018
• Elected Associate Editor Pediatric LINKS Newsletter Liaison, International Society for Heart & Lung Transplantation, 04/2018
• Council on Cardiovascular Surgery and Anesthesia Resident Prize Award, American Heart Association, 10/2017
• First Place, Research Study – Oral presentation, 41st Annual Midwest Pediatric Cardiology Society Meeting, 09/2017
• Chairman's Award - Best Outgoing Resident, Lincoln Medical and Mental Health Center, 06/2014
• Program Delegate Award, American Academy of Pediatrics, 10/2012 & 10/2013
• Dr. N. R. Motwani Gold Medal for Academic Excellence, Smt. N.H.L. Municipal Medical College, 04/2007
• Dr. C.R.Trivedi Gold Medal for highest grades in Preventive and Social Medicine, Smt. N.H.L. Municipal Medical College, 04/2007

Memberships

• American College of Cardiology
• American Heart Association
• American Medical Association
• The International Society for Heart & Lung Transplantation
• American Society of Transplantation
• Pediatric Heart Transplant Society
• Heart Failure Society of America
• Advanced Cardiac Therapies Improving Outcomes Network
• American Society for Artificial Internal Organs 
  
  
  
  

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 10/9/2024, Dr. Amdani has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.